AbCellera Biologics
ABCL
ABCL
130 hedge funds and large institutions have $1.1B invested in AbCellera Biologics in 2022 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 41 increasing their positions, 36 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
0.7% less ownership
Funds ownership: 40.68% → 39.97% (-0.7%)
32% less capital invested
Capital invested by funds: $1.63B → $1.1B (-$524M)
Holders
130
Holding in Top 10
9
Calls
$27.1M
Puts
$8.04M
Top Buyers
| 1 | +$72.9M | |
| 2 | +$28.3M | |
| 3 | +$20.3M | |
| 4 |
Millennium Management
New York
|
+$7.78M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$6.12M |
Top Sellers
| 1 | -$53.7M | |
| 2 | -$36.9M | |
| 3 | -$28M | |
| 4 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
-$20M |
| 5 |
CII
Capital International Inc
Los Angeles,
California
|
-$13.3M |